Los Angeles, Riverside, Orange County

What's New

Cyber unicorn: ForeScout hits billion-dollar mark

Israel-US agentless cybersecurity company, ForeScout, raises $76 million; mPrest and TravelersBox also announce million-dollar funding rounds. By Viva Sarah Press JANUARY 25, 2016, 10:38 AM A cyber unicorn (a private company valued at $1 billion or more) announced in Israel this week and two companies reeling in big bucks in the IoT sphere. ForeScout Technologies, the US-Israeli pioneer in agentless cybersecurity, has announced $76 million in additional financing to push its value to $1 billion. The additional capital will be used to expand global field operations, build a world-class support organization and increase R&D efforts to accelerate leadership in the underserved Internet of Things (IoT) security space, according to a company statement. ForeScout is headquartered in California and has a development center in Tel Aviv. The company – which boasts award-winning technology that provides the unique ability to see and control the rapidly growing population of unsecured and dark devices — was founded in 2000 by Chairman Prof. Hezy Yeshurun from Tel Aviv’s Faculty of Computer Science, CTO Oded Comay, and senior manager Doron Shikmoni. “It took 25 years for the world to get to five billion connected devices, but with the explosion of the IoT we’ll see around 30 billion by 2020—an entirely new approach to security is required,” said Michael DeCesare, ForeScout CEO & President. “Device proliferation and IoT deployments are easy entrances for cyber criminals if not detected and protected. With agentless visibility, intuitive automated controls and a commitment to integrating with leading security and IT management solutions, ForeScout is well-positioned to own the burgeoning IoT security market.” In related news, mPrest, a global provider of mission-critical monitoring and control software for the Internet of Things (IoT), has announced a $20 million Series A round of funding. The round was led by GE Ventures, the venture arm of GE, and OurCrowd, one of the world’s leading equity crowdfunding platforms. mPrest will use the investment to expand its international presence in the industrial and commercial markets and rapidly scale to meet the soaring needs of the IoT world. “mPrest is an exciting company with significant revenues, a real track record and a very promising future,” said Jon Medved, OurCrowd CEO. “Just as its Iron Dome technology has played an invaluable role in protecting millions of citizens, we are confident that mPrest’s real-time platform will deliver enormous value to its large industrial customers for years to come.” And Israeli startup TravelersBox, which offers a solution allowing travelers in airports to convert leftover foreign currency into usable digital currency, has announced a successful Series A funding round to the tune of $10 million. The company has raised $15.5 million to date. “There are more than three billion international travelers every year, and our mission is to provide an easy way for those travelers to regain the lost value of their unused foreign currency,” Tomer Zussman, founder and CEO of TravelersBox said in a statement. TravelersBox was founded in 2012. It has its headquarters in Gibraltar and an R&D center in Kadima. Illustration of unicorn by Shutterstock.com

Honda Turns to Israel for Help in Building Safer Vehicles

Honda Turns to Israel for Help in Building Safer Vehicles

World leaders, experts heading to CyberTech

Israel enjoys cyber superpower status as startups sell at least $3 billion of cyber security products and services in 2015. By Viva Sarah Press JANUARY 18, 2016, 4:12 PM Israeli cyber startups notched a very profitable year in 2015 and this upcoming year’s cyber arena looks ripe for even further growth. According to a new report, Israel exported at least $3 billion worth of products and services last year. Israel Export Institute figures show that Israel is a cyber superpower. New cyber technology startups – being formed and making exits – proves the country’s stronghold in the global cyber arena. In fact, state leaders and international cyber experts are heading over to Israel for the January 26-27 CyberTech in Israel convention. Hundreds of delegations from across the globe will attend CyberTech — the second largest exhibition of cyber technologies worldwide — including a large delegation from Japan, a US delegation led by the Deputy Secretary of Homeland Security, a delegation from developing countries organized by the World Bank, as well as a Canadian delegation comprising senior executives of Canada’s central banks. Also on the guest list: delegations from Germany, the UK, Italy, Holland, France, Australia, Singapore, Hong Kong, Taiwan, India, South Korea, Vietnam, the Philippines, Mexico, Brazil, Argentina, Kenya, South Africa, Ecuador, Panama, Guatemala, Colombia, Sweden, Ireland, Spain, Czech Republic, Romania, Albania, Estonia, the EU and NATO. The delegation from Japan includes a group looking for suitable technologies to secure the Tokyo Olympics 2020 from potential cyber threats. Israel Aerospace is leading a consortium of Israeli cyber security companies – including Check Point Software Technologies, Verint Systems, Bynet, ClearSky, CyberX, and ECI Telecom – that are hoping to attract Japanese interest with a special exhibit at CyberTech. The CyberTech event will allow B2B, startups, investors, government officials, military personnel, ambassadors and exhibition visitors to focus on networking, strengthening existing alliances, and forming new ones. CyberTech presents problem solving strategies and solutions to challenges in a wide range of sectors including finance, defense, transportation, utilities, R&D, energy, manufacturing, service sectors, health, media, and government.

13-Year-Old Israeli Girl Develops Satellite System for Producing Oxygen in

Author: Ruthie Blum A 13-year-old Israeli girl has invented a system for the production of oxygen in space, the Hebrew youth paper Ma’ariv L’Noar reported on Thursday, along with an interview with the budding tween scientist from Ramat Hasharon. The recent winner of the “Satellite Is Born” award from the Israel Space Agency, Roni Oron developed BioSat “to solve a problem for astronauts trying to prove that life on Mars is possible.” Oron said her satellite is “built like a large bubble on one side of which there is a mirror and the other is transparent, enabling the penetration of sunlight. In the middle there is a capsule, which will be made of a membrane through which air can pass but water cannot. Inside of it there will be water and algae, and outside there will be carbon dioxide. Through a process of photosynthesis, the satellite will produce oxygen. There will be additional mirrors inside the satellite that will enable sunlight to reach the capsule, but not by direct radiation, which would harm the algae.” Oron told Ma’ariv L’Noar about her parents’ support. “My father, an orthopedist, was very happy when I began my research,” she said. “From my mother I learned the wisdom of looking at life creatively.”

#BDS_Fail: Spanish government makes forced donation to Ariel University

After banning Samaria's Ariel University from a competition that it would have won, the government of Spain has been forced to contribute more than $100,000 to the university's coffers. Spain refused to allow Ariel University students to take part in a competition to design "green" environmentally-friendly buildings, which was meant to be open to students from all universities worldwide. Ariel University students reached the finals of the competition with their design, according to Yedioth Aharonoth. Their design, entitled "Abraham's Tent," garnered great international interest, but the boycott movement began working overtime to have the students banned from the competition for the simple fact that they study in Samaria. Eventually the anti-Israel activists succeeded, and even though the Israeli students had arrived in Spain in order to take part in the finals, they were informed by the Spanish construction ministry that funded the competition that they were being banned. The University responded by petitioning the decision via an attorney in Spain, suing the Spanish government for compensation and demanding that the students be allowed to return to the competition. The Spanish construction ministry reportedly tried to fight the petition, but after realizing they were going to lose embarrassingly, they decided to admit that they had discriminated against the students and the university and offered to pay 430,000 shekels in compensation. That amount was recently transferred to the university nuary 06, 2016 israelmatza.blogspot.com

New Israeli Treatment For Fibromyalgia Helped 100% Of Sufferers In New Stud

A clinical trial involving women diagnosed with fibromyalgia showed the painful condition improved in every one of the 48 who completed two months of hyperbaric oxygen therapy. Brain scans of the women before and after treatment gave credence to the theory that abnormal conditions in pain-related areas of the brain may be responsible for the syndrome. Above: The interior of a hyperbaric chamber at the Sagol Center for Hyperbaric Medicine and Research in Israel, used to treat patients with fibromyalgia in a recent trial. Courtesy of the Sagol Center for Hyperbaric Medicineand Research The interior of a hyperbaric chamber at the Sagol Center for Hyperbaric Medicine and Research in Israel, used to treat patients with fibromyalgia in a recent trial. Courtesy of the Sagol Center for Hyperbaric Medicine and Research – See more at: http://news.rice.edu/2015/06/02/hyperbaric-hope-for-fibromyalgia-sufferers-2/#sthash.yinyQ3dt.dpuf Hyperbaric Hope For Fibromyalgia Sufferers Mike Williams • Rice University Rice University part of Israel study to test novel treatment for little-understood condition Women who suffer from fibromyalgia benefit from a treatment regimen in a hyperbaric oxygen chamber, according to researchers at Rice University and institutes in Israel. A clinical trial involving women diagnosed with fibromyalgia showed the painful condition improved in every one of the 48 who completed two months of hyperbaric oxygen therapy. Brain scans of the women before and after treatment gave credence to the theory that abnormal conditions in pain-related areas of the brain may be responsible for the syndrome. Results of the study appear in the open-access journal PLOS One. Fibromyalgia is a chronic pain syndrome that can be accompanied by – and perhaps related to – other physical and mental conditions that include fatigue, cognitive impairment, irritable bowel syndrome and sleep disturbance. More than 90 percent of those diagnosed with the syndrome are women, said Eshel Ben-Jacob, a lead author of the proof-of-concept study who developed the analytical method used to show the association between patients’ improvement and changes in their brains. He is an adjunct professor of biosciences at Rice University, a senior investigator at Rice’s Center for Theoretical Biological Physics and a professor of physics and member of the Sagol School of Neuroscience at Tel Aviv University. “Symptoms in about 70 percent of the women who took part have to do with the interpretation of pain in their brains,” Ben-Jacob said. “They’re the ones who showed the most improvement with hyperbaric oxygen treatment. We found significant changes in their brain activity.” Scientists have not pinned down the syndrome’s cause, although another recent PLOS One study identified a possible RNA-based biomarker for its diagnosis. A variety of treatments from drugs to lifestyle changes have been tried to relieve patients’ suffering, with limited success, Ben-Jacob said. “Most people have never heard of fibromyalgia,” he said. “And many who have, including some medical doctors, don’t admit that this is a real disorder. I learned from my M.D. friends that this is not the only case in which disorders that target mainly women raise skepticism in the medical community as to whether they’re real or not. However, these days there are increasing efforts to understand the effect of gender on body disorders.” your medical guide December2015

ApiFix® Reports “Substantial Reduction” of Scoliosis Curvature at One-to-Th

July 13, 2015 08:30 AM Eastern Daylight Time CHARLESTON, S.C. & MISGAV, Israel--(BUSINESS WIRE)--ApiFix® Ltd. announced today that the company’s ApiFix® system, which has now been used to correct scoliosis in 50 adolescents since the system was approved for marketing in Europe, continues to demonstrate impressive results at one-to-three years of follow-up with 25 of these patients. “Scoliosis curve correction at one-to-three years follow-up is substantial for these adolescents. Equally important, patients are pain-free and happy with their new back shape. No implant failure has been observed,” said Prof. Yizhar Floman, M.D., principal investigator for the ApiFix® clinical study. ApiFix® is a commercial-stage company that has developed the CE-marked ApiFix® System — a non-fusion minimally invasive treatment alternative for Adolescent Idiopathic Scoliosis (AIS). Scoliosis surgery is the most invasive procedure in spine. The average procedure fuses 10 vertebrae together using 20 screws, resulting in significant and permanent loss of spine mobility. “There is a dire need for an alternative to today’s standard for scoliosis correction in adolescents 12 to 18 years old, the age when rapid growth typically occurs,” said Uri Arnin, CEO, headquartered in Misgav, Israel. “In 80 percent of these children, the cause of their scoliosis is ‘idiopathic’, or unknown. While the reduction in spine mobility is certainly a difficult consequence of long spinal fusions, which are the gold standard of treating scoliosis today, other critically important negative consequences include high chance for back pain and additional spine surgery during the first 20 years post-original surgery.” “Now, there’s the ApiFix system,” added Ted Bird, Chairman, based in Charleston, S.C., USA. “It is approved for sale in Europe. We are currently raising funding in order to fast-forward our sales-and-marketing efforts to launch a device that is designed to be a new standard for correcting scoliosis in adolescents.” A clinical study of The ApiFix® System led by Prof. Yizhar Floman, M.D. past President of the Israel Spine Society, published this year in the peer-reviewed medical journal Scoliosis concluded that “there are many drawbacks to the current gold standard of AIS surgery, which are almost nonexistent with the use of ApiFix: considerable blood loss leading to blood transfusions, neurologic deficit including spinal cord lesions, late infections, pseudoarthrosis, limitation of spinal motion also affecting non-fused levels, back pain and disc degeneration in the non-fused spinal segments. Almost all of these complications can be avoided by the use of Apifix.” Contacts Ronald Trahan Associates Ronald Trahan, APR, +1 508-359-4005, x108

Israel Ranks In Top Ten

Israel is the sixth-healthiest country in the world and is the only Middle Eastern country in the top 10, according to recent world health rankings by media outlet Bloomberg and reported in British newspaper The Independent. The rankings, which compiled data from the United Nations, the World Bank and the World Health Organization, placed Singapore in first place of 145 countries, with a "health grade" of 89.45 percent. Italy came in second, followed by Australia, Switzerland and Japan. After Israel came Spain, the Netherlands, Sweden and Germany. The United Kingdom ranked 21st and the United States 33rd. The U.S. came in after Costa Rica (No. 24), Denmark (26), Cuba (28) and the United Arab Emirates (30). Russia was in 97th place and Iraq in 98th. In last place was Swaziland, with a health grade of only 0.26 percent. The rankings were determined using a points system for positive and negative indicators of health, including life expectancy from birth, smoking rates among young people, and immunization rates.

Israeli health innovation startups wow at medical device conference in San

By Viva Sarah Press | October 20, 2015, 2:39 pm MobileODT, the company that uses mobile phones to detect cancer and other diseases, is this year’s winner of the 2015 MedTech Innovator competition. The Israeli startup beat out 300 early medtech startups from around the world and took home the cash prize of $200,000. The MedTech winners were announced recently at the AdvaMed 2015 conference in San Diego, tipped as one the leading gatherings of medical technology professionals in North America. Briteseed, an American medical diagnostic imaging company, won second place and a $50,000 cash prize. MedAware, the Israeli company that leverages big data and sophisticated algorithms to stop prescription errors, and uBiome, the San Francisco-based company behind a self-sampling microbiome testing service, were runners up in the contest. The four finalists presented their companies and the winner was selected by live audience vote.

High-pressure oxygen for fibromyalgia

Israeli study finds new treatment for pain syndrome reduces or eliminates need for medication. Hyperbaric oxygen chambers are used in many countries to treat patients with embolisms, burns, carbon monoxide poisoning and decompression sickness. Now, an Israeli study shows that the high-pressure pure oxygen treatments are also helpful for people who suffer from fibromyalgia, a chronic pain syndrome affecting an estimated one in 70 Americans, most of them women. The study, published recently in the journal PLoS ONE, describes how the researchers were able to map the malfunctioning brain regions responsible for the syndrome, and used hyperbaric oxygen treatment to drastically reduce, or even eliminate, the need for pain medication. “As a physician, the most important finding for me is that 70 percent of the patients could recover from their fibromyalgia symptoms,” said Dr. Shai Efrati, director of the Sagol Center for Hyperbaric Medicine and Research and head of R&D at Assaf Harofeh Medical Center in Tzrifin, and a faculty member at the Sagol School of Neuroscience at Tel Aviv University (TAU). Fibromyalgia can be triggered by head trauma, a neurological infection or severe emotional stress, and causes symptoms such as musculoskeletal pain, fatigue, memory loss and mood swings. Few therapies have been found to be effective in assuaging its symptoms. “It means that brain repair, including neuronal regeneration, is possible even for chronic, long-lasting pain syndromes.” Efrati and his team exposed study participants to two months of hyberbaric oxygen therapy. They found significant changes in the brain activity and symptoms of 70 percent of participants. The trial involved 60 women who had been diagnosed with fibromyalgia at least two years earlier. Half of the 48 patients who completed the therapy received 40 hyperbaric oxygen treatments — 90-minute treatments exposing patients to pure oxygen at twice the atmospheric pressure, five days a week over the course of two months. Not just treating symptoms The successful treatment enabled patients to drastically reduce or even eliminate their use of pain medications. “The intake of the drugs eased the pain but did not reverse the condition. But hyperbaric oxygen treatments did reverse the condition,” said Efrati, who added that the findings are significant enough to warrant further study. “Hyperbaric oxygen treatments are designed to address the actual cause of fibromyalgia — the brain pathology responsible for the syndrome,” he said. “It means that brain repair, including neuronal regeneration, is possible even for chronic, long-lasting pain syndromes, and we can and should aim for that in any future treatment development.” The researchers did find some discrepancies among patients depending on the origin of the condition. When fibromyalgia was triggered by a traumatic brain injury, for example, they witnessed a complete resolution without any need for further treatment. But when the trigger was attributed to other causes, such as fever-related diseases, patients required periodic maintenance therapy. The researchers are continuing to conduct comprehensive studies on the renewal of brain tissue under hyperbaric conditions. A previous study led by Efrati and the late Prof. Eshel Ben-Jacob, published in the same journal in 2013, showed that hyperbaric oxygen therapy increased neuronal activity in post-stroke patients and may be effective in treating and preventing many other brain disorders. The current study was carried out by Efrati, Ben-Jacob and scientists affiliated with TAU, Assaf Harofeh Medical Center, Ben-Gurion University, Soroka Medical Center in Beersheva, Tel Aviv Sourasky Medical Center, Ashkelon Academic College, Kaplan Medical Center in Rehovot and Rice University in Texas. Israel 21c

Israeli Researcher Makes Key Breakthrough In Combating Antibiotic Resistanc

By NoCamels Team June 09, 2015 0 Comments At its annual assembly in Geneva last week, the World Health Organization approved a radical and far-reaching plan to slow the rapid, extensive spread of antibiotic resistance around the world. The plan hopes to curb the rise caused by an unchecked use of antibiotics and lack of new antibiotics on the market. Now Tel Aviv University research published in PNAS introduces a promising new tool: a two-pronged system to combat this dangerous situation. The system wipes out antibiotic resistance in selected bacteria, and renders other bacteria more sensitive to antibiotics. The research, led by Prof. Udi Qimron is based on bacterial viruses called “phages”, which transfer “edited” DNA into resistant bacteria to kill off resistant strains and make others more sensitive to antibiotics. According to the researchers, the system, if ultimately applied to pathogens on hospital surfaces or medical personnel’s hands, could turn the tide on untreatable, often lethal bacterial infections. “Since there are only a few pathogens in hospitals that cause most of the antibiotic-resistance infections, we wish to specifically design appropriate sensitization treatments for each one of them,” Prof. Qimron says. “We will have to choose suitable combinations of DNA-delivering phages that would deliver the DNA into pathogens, and the suitable combination of ‘killing’ phages that could select the re-sensitized pathogens.” “Antibiotic-resistant pathogens constitute an increasing threat because antibiotics are designed to select resistant pathogens over sensitive ones,” Prof. Qimron says. “The injected DNA does two things: It eliminates the genes that cause resistance to antibiotics, and it confers protection against lethal phages. “We managed to devise a way to restore antibiotic sensitivity to drug-resistant bacteria, and also prevent the transfer of genes that create that resistance among bacteria,” he continues. Earlier research by Prof. Qimron revealed that bacteria could be sensitized to certain antibiotics — and that specific chemical agents could “choose” those bacteria more susceptible to antibiotics. His strategy harnesses the CRISPR-Cas system — a bacterial DNA-reprogramming system Prof. Qimron pioneered — as a tool to expand on established principles. According to the researchers, “selective pressure” exerted by antibiotics renders most bacteria resistant to them — hence the epidemic of lethal resistant infections in hospitals. No counter-selection pressure for sensitization of antibiotics is currently available. Prof. Qimron’s strategy actually combats this pressure — selecting for the population of pathogens exhibiting antibiotic sensitivity. “We believe that this strategy, in addition to disinfection, could significantly render infections once again treatable by antibiotics,” said Prof. Qimron. Prof. Qimron and his team are now poised to apply the CRISPR/phage system onpseudomonas aeruginosa — one of the world’s most prevalent antibiotic-resistant pathogens involved in hospital-acquired infections — and to test whether bacterial sensitization works in a more complex microbial environment: the mouse cage. Prof. Qimron is a member of the Department of Clinical Microbiology and Immunology at TAU’s Sackler Faculty of Medicine.

Researchers at Israel's Weitzman Institute First

To Grow Immune System Cells In Lab by ISRAEL21c | 05.21.15 5:55 pm The global science community is looking to Rehovot, where a team of Israeli scientists at the Weizmann Institute managed to grow lymphatic cells in the lab for the first time ever. For over a century, scientists have debated the origins of the lymphatic system—a parallel system to the blood vessels that serves as a conduit for everything from immune cells to fat molecules to cancer cells. This issue has now been resolved by Dr. Karina Yaniv of the Weizmann Institute’s Biological Regulation Department. In a study reported in Nature, Yaniv and her team revealed how the lymphatic system develops in the embryo. In the initial stages of the research project, Yaniv’s team members Julian Nicenboim and Dr. Guy Malkinson obtained images of developing zebrafish embryos, whose transparent bodies make it possible to document embryonic development in real time over several days. The scientists then played the movies backward, to identify the point at which the lymphatic system began to form. To their surprise, they discovered that the cells that give rise to lymphatic vessels always originated in the same part of the embryo’s major vein. In that spot, the scientists found a niche of angioblasts, the same cells that a hundred years earlier were thought to be the source of lymph vessels, but were later neglected by researchers. An in-depth genetic analysis, performed with the participation of graduate students Tal Lupo and Lihee Asaf, pointed to a gene called WNT5B, which was revealed to be the factor prompting stem cells to differentiate into lymphatic cells. When postdoctoral fellow Dr. Yogev Sela added WNT5B to human embryonic stem cells, these cells indeed differentiated into lymphatic cells—the first time such cells had been grown in the lab. “We started out by imaging zebrafish, and ended up finding a factor that makes it possible to create lymphatic cells,” said Yaniv. “That’s the beauty of research in developmental biology: The embryo holds the answers, and all we have to do is watch and learn.” The new research not only answers a longstanding question of how the lymph system arises, but can also provide important insights into disease, from metastasis to the abnormal accumulation of lymph fluids, particularly in the wake of surgery to remove cancerous tumors. The research was performed in collaboration with the laboratories of Prof. Itai Yanai from the Technion—Israel Institute of Technology, Dr. Jacob Hanna of Weizmann’s Molecular Genetics Department, and Prof. Nathan Lawson of the University of Massachusetts.

BDS SUPPORTERS USE ISRAELI & JEWISH MEDICAL DISCOVERIES AND SERVICES

The BDS supporters do not hesitate to make use of the medical discoveries and services of Israeli and other Jewish doctors and institutions. Following is a very abbreviated list: Blood group identification for blood transfusion, Smallpox eradication, Penicillin, Diphtheria & Tetanus Antitoxin, Hepatitis-B Vaccine, Mammograms, Polio Vaccine, Polio vaccine, Aspirin, Warfarin (prevention of heart attacks & strokes), Cancer chemotherapy, Breaking the genetic code, Nuclear magnetic resonance, Flexible endoscope, Streptomycin (Tuberculosis), Cancer chemotherapy, Lasik eye surgery, Cardiac defibrillator, Controlled chlorination of drinking water supplies, Medical treatment at Israeli hospitals: Over 1500 wounded Syrians, Treated daughter of a high Hamas leader, Treated niece of Ayatollah Khomeini for reproductive issues and many more. It has been estimated that, depending on the assumptions used, the number of lives saved by Israeli and other Jewish discoveries has been 2.8-4.3 BILLION!! For more information, see www.jinfo.org/Life_Savers.html.

Israel’s Exelon inventor sees an end to Alzheimer’s

BY DAVID SHAMAH April 22, 2015, 5:08 pm 9 Dr. Marta Weinstock-Rosin, inventor of Exelon, a drug that improves memory and slows its decline in subjects with Alzheimer’s disease, is a big believer in the ability of medical science to help people live longer and better-quality lives. Alzheimer’s is a modern phenomenon; 100 years ago you never saw people like that, because they all died of other diseases before the brain degenerated.”And eventually, she believes, a preventive treatment will be found for Alzheimer’s and the other maladies of the brain, along with cancer, heart disease, and the other great medical challenges of the modern era. Exelon, the drug she created to treat Alzheimer’s, is just the beginning. “A young person today may live to see a time when Alzheimer’s and many of the other great challenges are preventable,” she said.Rivastigmine, commercially known as Exelon, is one of the most important drugs to have emerged from Israeli medical research labs in recent years. In recognition of this fact, its chief developer, Weinstock-Rosin, was awarded the Israel Prize for Medicine last year for her work. In many ways, Exelon, and its inventor, paved new paths in Israeli medicine, and Israeli society. Weinstock-Rosin, who is Orthodox, was born in Vienna and fled with her family to Britain in 1939, narrowly escaping from the Nazis. She came to Israel with her family in 1969, and became a professor at Hebrew University in 1981. In 1983, she became head of the Pharmacology department at the Hebrew University (now part of the Institute for Drug Research) in the Faculty of Medicine.Weinstock-Rosin’s drug Rivastigmine was incorporated by Novartis into the Exelon Patch, the first and only FDA-approved skin patch for treatment of Alzheimer’s disease, in which many researchers believe the cognitive decline results from a loss a brain neural transmitter called acetylcholine. Acetylcholine is necessary for communication between nerve cells. Rivastigmine prevents the breakdown of acetylcholine by an enzyme called acetylcholinesterase. Weinstock-Rosin’s research showed that by so doing it can slow the progress of memory loss in Alzheimer’s disease.As there currently is no cure for Alzheimer’s, Exelon is considered one of the more effective treatments for the disease. Used by patients either twice a day in capsules or once a day in patch form, Novartis sold more than $1 billion worth of Exelon in 2013.Novartis acquired Exelon from the Hebrew University’s technology transfer company, Yissum, which since 1964 has established numerous companies based on research done by Hebrew U scientists, including road safety innovator Mobileye. Altogether, products based on Hebrew University technologies that have been commercialized by Yissum generate $2 billion in annual sales. Weinstock-Rosin’s current research involves a drug called Ladostigil, originally developed together with Prof. Moussa Youdim of the Technion and Teva pharmaceuticals to treat Alzheimers like rivastigmine. Weinstock-Rosin discovered that at a much lower dose it can prevent the deterioration of memory in aging rats by a different mechanism of action and may also be able to do this in mild cognitive impairment (MCI), an early stages of Alzheimer’s disease in humans. The drug is now undergoing a three-year Phase II clinical trial in Israel and Europe in subjects with MCI for the prevention of Alzheimer’s disease.For doctors, researching diseases of the brain is the next great challenge, said Weinstock-Rosin. “We have done a great deal to keep people alive longer, but now we have to help them live better-quality lives by discovering ways to slow down or even prevent mental deterioration. What good will it be to live to be 150 but without mental faculties?”

Israeli-American Team Unveils Revolutionary Drug in Fight Against Skin Canc

Team member Jacob Schachter of Sheba Medical Center believes the new treatment 'will turn melanoma into a treatable chronic disease.' Nechama Duek Published: 06.08.14, 16:32 / Israel Culture A groundbreaking biological treatment for cancer jointly developed by Israeli and American researchers has been presented at an international conference on cancer research in Chicago. "This medicine is a miracle cure - it's a real breakthrough," says Prof. Jacob Schachter, head of research and treatment of melanoma and skin cancer at Sheba Medical Center, who is part of the international research team for the medicine. The new treatment comes from the field of immunotherapy, which helps the immune system fight cancer, unlike chemotherapy, which attacks the tumor itself. There are various types of cancerous tumors, such as melanoma, that use a "shield" to protect themselves from being identified by the immune system. The new medicine paralyzes this type of screening mechanism, so the immune system can recognize the cancer and attack it. The results of the international research suggest that using the medicine Pembrolizumab, also known as MK-3475, yields impressive survival rates in patients with advanced cancer, with 69 percent surviving one year and 63 percent surviving 18 months. Without this treatment, patients with metastatic melanoma die from the disease within 4-5 months, after reaching stage four cancer. The research tested 41,818 patients, 1,800 of them in Israel. The research took place over a decade, while the clinical stage took four years. The new medicine, which belongs to a new generation of biological drugs, yielded extraordinary results to the point that the FDA approved it for "compassionate use" (the use of an investigational drug outside a clinical trial by patients with life-threatening conditions) and it will be given for free to terminally ill patients. It is also be fast tracked for approval, which is expected by October. "One of my patients who suffered metastatic melanoma in very critical condition entered the trial, and within six weeks his body was completely clean of cancer," said Schachter. He stressed that because of the biological nature of the drug; its side effects are minimal and allows patients optimal quality of life. Merck, the American company that developed the drug, has a department in Israel called MSD, which operates a research division working in tandem with medical centers in Israel."We are on our way to turn melanoma a treatable chronic disease," said Schachter. "We are also seeing positive results in other types of cancer such as the urinary bladder, head neck and lungs". Prof. Alise Reicin, who heads the American team that developed the drug, termed it "definitely a breakthrough in the war against cancer". Thousands of doctors and researchers from around the world attended the conference of the American Society for Clinical Oncology, an annual event focusing on the latest medicine and research in cancer treatment. A significant number of this year's lectures were dedicated to research in biological medicine and immunotherapy, which are seen as the new generation of cancer treatment

Successful Kosher Food & Wine Experience in US, Europe, and Israel "Getting the Message Out" Says Kedem The 9th annual Kosher Food and Wine Experience sponsored by Kedem (Royal Wine Corporation)takes place this evening at the Metropolitan Pavilion in Manhattan. More than 1,000 bottles of wines and spirits from the US, France , Israel, and other fine wine regions around the world will be sampled. Initially held only in New York, the event has expanded to such cities as Miami, Paris, Tel Aviv and London. Nathan Herzog, the Executive Vice President for Royal Wines says that “ each event has its own flavor and we always make sure to get kosher winemakers from all over the globe so people can talk directly with them”. He adds “it’s the best vehicle to get the message directly to the consumers of the great kosher wines available today”. The KFWE in New York is divided into two parts, the first for trade and professionals and the second for some 1800 food connoisseurs who in addition to the wines can taste great foods from some of the New York region’s finest restaurants and caterers. Last week, more than 800 people attended a similar event in London. Wines from Israel are very much in demand - there is a lot of interest, many new wines and vintages, and a lot of growth and movement, states Jay Buchsbaum, VP marketing and Director of Wine Education, the Royal Wine Corporation /Kedem. “The single strongest growth area in the kosher wine world is Israel, hands down. We almost can’t bring it in fast enough and some of the wineries can’t produce enough volume to satisfy the U.S demand”. To date Royal Wine offers more than 20 different Israeli wineries in its portfolio. Kosher wine in America is big business – upwards of $28 million in sales, according to estimates made several years ago. kosher Today

New Jersey Rabbi develops app to support Israeli products

A free application for those who want to support Israel by helping Israeli made products is now downloadable for all major smart phones. The new app, Am Yisrael Buy was created by Rabbi Daniel M. Cohen, spiritual leader of Temple Sharey Tefilo- – Israel in South Orange New Jersey. “There is an international movement called BDS – Boycott, Divestment and Sanctions – aimed at boycotting Israel and its products” said Cohen. “The movement demonizes Israel and has, as some of its leading proponents, anti—Semites whose ultimate goal is the destruction of the State of Israel. When I learned there are BDS apps that make it easier to boycott Israeli products and goods and spread their hatred, and then found there was no commensurate Pro – Israel app, I just had to act. That was the impetus for creating Am Yisrael Buy.” Initially Rabbi Cohen turned to some of his colleagues in the rabbinic community to see if they would join him in helping to promote an app for Israel. Once they agreed, he contacted a developer to help him create the app. The developer had some good ideas but was moving too slowly, so Rabbi Cohen decided to create it himself using a template – driven app development software tool. He taught himself to use the interface and Am Yisrael Buy was born. The app offers a list of Israeli made products, and where to buy them, as well as additional ways to support Israel. “As I was putting together the list I realized there were other ways to support Israel, so I added a section with some of the media outlets that cover Israel, outlets that help expose media bias against Israel, and included a number of ways people can donate to Pro – Israel organizations.” Added Cohen Jewish Advocate 10/10/14

Online Gift Stores Fight Boycott of Israel

With the continued growth of online shopping, Israeli online gift stores are spending more and promoting their products abroad in an effort to encourage Jews and non-Jews around the world to support Israel's economy - and challenge the BDS campaign against Israel. They are marking their products with "Made in Israel" in a clear sign for buyers to know of the Israeli designers. While much of the cheaper products are manufactured in China, many of the fine arts and crafts are produced in Israel. IsraelGiftStore - Shop Now The BDS boycott, divesture and sanctions campaign waged against Israel has steadily advanced around the world. However, in the past 3 years, Israel's Central Bureau of Statistics reports there has been an increase in exports each year between 3-6%. This is good news for the online stores which are targeting new markets. The focus of these Israeli web stores has been moving to markets beyond the Jewish community including the Christian supporters, and countries in Latin America and Asia which have strong economies. For these, the emphasis tends to be more with products from the Holy land, but not necessarily religious items. Many Jewish and Christian organizations and individuals are vocally advocating for Israel, but most still shop in their local communities (where much is imported from Asia) or online for the best price. The online stores are suggesting that the priority should be "buying blue and white". One such company, www.IsraelGiftStore.com carries only products that are designed and manufactured in Israel, including the packaging. It brands its products as higher quality with lower margins and quick service to encourage the online shopping experience. IsraelGiftStore - Shop Now "We started the Israel Gift Store after seeing the force of the BDS campaign and the growing divestures of companies doing business with Israel. We felt we needed to take a proactive stance to show the amazing creativity, diversity and culture of our country. We do this through beautiful products, and through our promotions," said Tali Omer, founder of the Israel Gift Store. "It's a whole new ballgame with the social media promotions, and not any less expensive than operating a physical store. But the rewards for promoting Israel abroad are so much greater," Tali explains. The international reach of the online stores has the added advantage of fewer peaks and valleys in sales. Holidays and special events in other countries and cultures occur regularly, to create a more even ordering for manufacturers. With the statistics proving positive, the advantages of the online gift stores work both for the economy, the producers and the consumers. Thank you! We appreciate your business and your support of Israel. Tali Omer Israel Gift Store

Christians United For Israel

ornament 2014 Dear Friend , Christians United for Israel (CUFI) is the largest pro-Israel organization in the United States with over one million members and one of the leading Christian grassroots movements in the world. We have only 25 staff, but serve over one million members and conduct over 40 pro-Israel events every month. Statement of Purpose The purpose of Christians United For Israel (CUFI) is to provide a national association through which every pro-Israel church, parachurch organization, ministry or individual in America can speak and act with one voice in support of Israel in matters related to Biblical issues. BDS (Boycott, Divestment and Sanctions) is the latest effort to attack the Jewish people and delegitimize the Jewish State. The people promoting BDS are Israel haters who are trying to treat Israel like apartheid South Africa. They're hoping you'll forget that Israel is one of the most racially diverse countries in the world. They're hoping you'll not know that the freest Arabs in the Middle East are the Arab citizens of the Jewish State of Israel. They're hoping you won't see in their boycott of Jewish products and scholars a parallel to the Nazi boycott of Jewish merchants and academics decades ago. We are pushing back against the boycott of Israeli goods by purchasing Israeli goods. That's why our CUFI Christmas ornament is made in Israel! For your gift of $20 or more you receive a silver made in Israel CUFI Christmas Ornament. Or for your gift of $35 or more you will receive both the silver and gold made in Israel CUFI Christmas ornaments. May God Bless You and Those that You Love, Pastor John Hagee David Brog Chairman Executive Director Stand with Israel - Donate now! info@cufi.org

Friends of Israel

Monna Young Nov 11th, 2:14pm If you've never heard of us before: Hello from Sussex Friends of Israel! We are a group who have just started up in response to intense and aggressive demonstrations in our town, by the Boycott Divestment and Sanctions movement outside shops that sell Israeli produce. Upset and disturbed by weekly harassment, chanting and shouting of lies and hatred by these activists outside these shops, members of the Jewish and Christian community of Brighton began a counter-protest, forming the group which is now known as Sussex Friends of Israel. We've just passed our second anniversary since we first started counter-protesting against the BDS, giving out pro-Israel leaflets, holding our own rallies, talking and engaging the public and giving them another narrative and another side to the story. Members from all religions and backgrounds have thanked us for being a presence in Brighton, UK,, not only because they have also experienced harassment by the BDS and other groups, but because they feel marginalised and threatened by such a divisive, loud and aggressive movement on their streets. Would you visit and Like (or/and Share?) our page and thus support our small but ever growing online community which aims to promote and share the truth about Israel and the wider Jewish Community? Here is Sussex Friends of Israel’s link! https://www.facebook.com/pages/Sussex-Friends-Of-Israel/521248807933259?fref=ts

How Can You Help Israel?

During these difficult times, when we can give less to help others, the Israeli organizations that rely on U.S. donations are struggling like never before. The drop in the value of the U.S. dollar means charitable donations buy far less than in the recent past. And with food prices soaring worldwide, the numbers of truly poor, keep rising. The ripple effect from the U.S. financial crisis is devastating to charities and businesses in Israel. Israel's economy has recovered admirably, but there is still suffering and crushing poverty in much of the country. Self defense is expensive. Rebuilding war-ravaged lives, homes and businesses requires support. Most social services have been reduced drastically. Over 1.6 million people in Israel live below the poverty line. One in every three Israeli children is growing up poor- without enough food, without dental care, or shoes that fit. This store is our small attempt to make a difference. Our goal is to make high quality Israeli products easier to find and purchase for U.S. consumers. We urge our customers to support both America and Israel by purchasing MADE IN U.S.A. and MADE IN ISRAEL products whenever possible. Conscious spending for everyday needs in this way helps good people keep their jobs. It is a simple way to help counter the economic damage done by terrorists. Our warehouse is in Baltimore, so you wont have to wait weeks or pay exhorbitant shipping rates to buy MADE IN ISRAEL items. Please browse through our wonderful selection of THOUSANDS of useful, affordable and beautiful items, with favorite brands like Ahava, Dr. Fischer, Elite, Osem, Halutza, Neca 7, Ayala Bar, Yair Emanuel, Natural Formula, Safed Candles, and with hard-to-find items from small manufacturers and artists too. 100% of net profits from our internet sales are donated to Israeli charities. Israelproducts.com

ISRAELI BEER COMES TO THE U.S.

Malka Beer has become the first brand of Israeli craft beer to become available in the United States, and Illinois is now one of the first US markets to support it, distributed by Chicago owned and operated Louis Glunz Beer and imported by Sublime Imports. Located in the upper Galilee town of Yehiam (pronounced YEH-HEE-YAHM), at the foot of the 12th century Montfort Castle, Malka is one of the first micro-breweries in Israel. Malka maintains a tradition of hand-crafting small batches of beer, specializing in traditional Belgian, German, and English styles while imparting a local Israeli twist-using natural water from the Ga�aton Springs and local flavors. You can discover more about Malka Beer via their website: http://malkabeer.co.il/en/ Questions about where to find Malka Beer can be directed to your favorite local craft beer retailer and/or their distributor: Louis Glunz Beer via phone or email: (847) 676-9500 and info@glunzbeers.com

American Business Thrives in Israel

Amazon announced during a visit to Israel in October ,"We are setting up in Israel to support our cloud activity". Amazon's service and sales center, to open in 2014, will also service the Middle East and Africa. General Motors' Israel R&D facility is working on a self driving, self parking car that decreases the number of auto accidents. Asurion Corporation, a provider of technical support to the wireless phone industry, brought Israeli high-tech startup Soluto for$130 million. (Assaf Glad, Al-Monitor; David Shamah, Times of Israel; Orr Hirschauge, Ha'aretz)

VIEW BLOG AND SUBMIT YOUR COMMENTS

In many product categories - especially food, wine, cosmetics HBA, and women's apparel - the BLOG feature provides information, product suggestions, and the opportunity for visitors to submit their comments, recommendatons, and suggestions. Tell us which foods, wines and other products you particularly like. Email us at: blog@buyisraelgoods.org. Submissions must be reviewed before publicaton to prevent vandalism of this site.

Disclaimer This site was developed and will be expanded and maintained, by California Israel Chamber of Commerce.
©Copyright 2008
BUYISRAELGOODS, and SHOP BIG. SHOP ISRAEL. are trademarks of the America-Israel Chamber of Commerce Chicago Registered in the U.S. Patent and Trademark Office.